Company intelligence / Profile preview

Newton Biocapital

Ownership: Private
Development stage: Other

Overview

Newton Biocapital invests in early-stage life sciences and biotech companies developing solutions for chronic diseases in Europe and Japan. It supports its portfolio with hands-on involvement and strategic guidance but does not develop drugs or technologies itself.

Therapeutic areas: Other
Modalities: N/A
Industry: Investors

Partnerships

Co-investors include major funds such as Eli Lilly and Company, Novo Holdings among others for specific deals

Beyond the preview

Go deeper on Newton Biocapital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Newton Biocapital.

Explore the full profile